GlassScriptPhysician profile
David Bryan Engle
NPI 1487611760
$7,336.38
in general payments reported to CMS, 2019-2025
31 companies · $1,734 in 2025
The $1,734 reported for 2025 was more than what 77% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $375 · 2021: $963 · 2022: $519 · 2023: $856 · 2024: $2,065 · 2025: $1,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,240 · Travel and Lodging: $824 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500 · Education: $90.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,240.01 |
| Travel and Lodging | $823.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
| Education | $90.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,353.05 | 2019-2025 | Lynparza |
| Medtronic, INC. | $1,076.71 | 2022-2024 | Ligasure, Signia, Sonicision |
| Glaxosmithkline, LLC. | $988.17 | 2019-2025 | Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $948.83 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Eisai INC. | $526.54 | 2019-2025 | |
| Intuitive Surgical, INC. | $500.00 | 2025 | |
| Abbvie INC. | $358.26 | 2019-2025 | |
| Tesaro, INC. | $309.13 | 2019 | |
| Clovis Oncology, INC. | $264.79 | 2019-2022 | |
| Daiichi Sankyo INC. | $126.66 | 2024-2025 | Enhertu, Injectafer |
| Pfizer INC. | $121.94 | 2024-2025 | |
| Stryker Corporation | $114.49 | 2019 | |
| Seagen INC. | $113.50 | 2022-2023 | Tivdak |
| Myriad Genetic Laboratories, INC. | $60.58 | 2022-2024 | Myrisk, Precisetumor |
| Immunogen, INC. | $55.15 | 2023 | Elahere |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $50.26 | 2023-2024 | Exparel |
| Conmed Corporation | $46.65 | 2025 | Airseal |
| Tempus Ai, INC | $35.09 | 2025 | Xt Cdx |
| Verastem, INC. | $34.89 | 2025 | Avmapki Fakzynja Co-Pack |
| Caris Mpi, INC. | $32.98 | 2025 | Mi Cancer Seek |
| Monaghan Medical Corporation | $29.72 | 2024 | Aeroeclipse |
| Avanos Medical | $23.88 | 2019 | |
| Northgate Technologies, INC. | $21.13 | 2024 | Stimsite |
| Provepharm INC. | $20.58 | 2025 | Bludigo |
| Lsi Solutions INC | $20.15 | 2023 | Fornisee |
| Tersera Therapeutics LLC | $18.70 | 2020 | |
| Fennec Pharmaceuticals, INC. | $18.34 | 2025 | Fyarro |
| Corcept Therapeutics | $18.30 | 2025 | Korlym |
| Kyowa Kirin, INC. | $16.99 | 2019 | |
| Amgen INC. | $15.82 | 2019 | |
| Bard Access Systems, INC. | $15.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Engle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.